MimiVax reports Phase II data for glioblastoma immunotherapy
MimiVax LLC (Buffalo, N.Y.) reported interim data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM
Gathering data...
MimiVax LLC (Buffalo, N.Y.) reported interim data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM